Xbrane Biopharma: BLA re-submitted - Redeye

Redeye leaves a comment on Xbrane’s press release stating that it now has re-submitted its Lucentis biosimilar’s BLA to the FDA. With expected 6-month review time a new BsUFA date is anticipated by mid-2025.

Länk till analysen i sin helhet: https://www.redeye.se/research/1066430/xbrane-biopharma-bla-re-submitted?utm_source=finwire&utm_medium=RSS